3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
97
Neoplasms
28
Carcinoma, Non-Small-Cell Lung
27
Neoplasm Metastasis
23
Urinary Bladder Neoplasms
17
Colorectal Neoplasms
17
Sarcoma
15
Lung Neoplasms
14
Biliary Tract Neoplasms
13
Ovarian Neoplasms
12
Lymphoma, Large B-Cell, Diffuse
12
Breast Neoplasms
12
Lymphoma
10
Cholangiocarcinoma
10
Recurrence
9
Hodgkin Disease
8
Carcinoma, Transitional Cell
8
Adenocarcinoma
8
Lymphoma, Non-Hodgkin
7
Triple Negative Breast Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
6
Lymphoma, Follicular
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Rectal Neoplasms
5
Gastrointestinal Neoplasms
5
Colonic Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Multiple Myeloma
4
Lymphoma, T-Cell, Peripheral
4
Interventions
Cisplatin
2
tislelizumab
1
pembrolizumab
1
enfortumab vedotin
1
cabozantinib
1
VMBP protocol
1
Pemetrexed
1
Nivolumab
1
Neoadjuvant Therapy
1
Gemcitabine
1
Docetaxel
1
Carboplatin
1
Administration, Intravesical
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urologic Neoplasms
×
Gemcitabine
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA